Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Liabilities: 2013-2025

Historic Total Liabilities for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $428.7 million.

  • Coherus Oncology's Total Liabilities fell 27.70% to $428.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $428.7 million, marking a year-over-year decrease of 27.70%. This contributed to the annual value of $580.5 million for FY2024, which is 29.47% down from last year.
  • Coherus Oncology's Total Liabilities amounted to $428.7 million in Q3 2025, which was up 34.13% from $319.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Total Liabilities high stood at $845.4 million for Q1 2024, and its period low was $319.6 million during Q2 2025.
  • In the last 3 years, Coherus Oncology's Total Liabilities had a median value of $598.9 million in 2023 and averaged $624.0 million.
  • As far as peak fluctuations go, Coherus Oncology's Total Liabilities spiked by 82.90% in 2021, and later plummeted by 57.89% in 2025.
  • Over the past 5 years, Coherus Oncology's Total Liabilities (Quarterly) stood at $581.6 million in 2021, then rose by 6.30% to $618.3 million in 2022, then soared by 33.12% to $823.0 million in 2023, then decreased by 29.47% to $580.5 million in 2024, then dropped by 27.70% to $428.7 million in 2025.
  • Its Total Liabilities was $428.7 million in Q3 2025, compared to $319.6 million in Q2 2025 and $554.5 million in Q1 2025.